Ameriprise
TBPH icon

Ameriprise’s Theravance Biopharma TBPH Stock Holding History

Ameriprise’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-63,731
Closed -$569K – 4122
2025
Q1 		$569K Sell
63,731
-37,076
-37% -$345K ﹤0.01% 3436
2024
Q4 		$949K Sell
100,807
-10,825
-10% -$98.5K ﹤0.01% 3256
2024
Q3 		$900K Buy
111,632
+250
+0.2% +$2.17K ﹤0.01% 3265
2024
Q2 		$945K Sell
111,382
-390
-0.3% -$3.52K ﹤0.01% 3178
2024
Q1 		$1M Buy
111,772
+78,393
+235% +$726K ﹤0.01% 3168
2023
Q4 		$375K Buy
+33,379
New +$336K ﹤0.01% 3551
2023
Q2 		– Sell
-17,030
Closed -$185K – 4001
2023
Q1 		$185K Buy
17,030
+600
+4% +$6.34K ﹤0.01% 3745
2022
Q4 		$185K Buy
+16,430
New +$173K ﹤0.01% 3724
2021
Q3 		– Sell
-11,310
Closed -$164K – 3959
2021
Q2 		$164K Sell
11,310
-4,121
-27% -$77.4K ﹤0.01% 3781
2021
Q1 		$315K Sell
15,431
-330,075
-96% -$6.27M ﹤0.01% 3584
2020
Q4 		$6.14M Sell
345,506
-112,537
-25% -$2.02M ﹤0.01% 2127
2020
Q3 		$6.77M Sell
458,043
-1,044,830
-70% -$19.6M ﹤0.01% 1858
2020
Q2 		$31.5M Sell
1,502,873
-73,842
-5% -$1.9M 0.01% 818
2020
Q1 		$36.4M Buy
1,576,715
+1,226,134
+350% +$30.7M 0.02% 664
2019
Q4 		$9.08M Sell
350,581
-69,186
-16% -$1.34M ﹤0.01% 1826
2019
Q3 		$8.18M Sell
419,767
-41,793
-9% -$844K ﹤0.01% 1857
2019
Q2 		$7.54M Buy
+461,560
New +$9.35M ﹤0.01% 1939
2016
Q4 		– Sell
-46,273
Closed -$1.68M – 3945
2016
Q3 		$1.68M Buy
+46,273
New +$1.29M ﹤0.01% 2656
2014
Q4 		– Sell
-1,163
Closed -$26K – 4343
2014
Q3 		$26K Buy
1,163
+55
+5% +$1.6K ﹤0.01% 4346
2014
Q2 		$35K Buy
+1,108
New +$33.4K ﹤0.01% 4064

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameriprise's TBPH Position: Q2 2025 in Review

Ameriprise sold out of Theravance Biopharma (TBPH) in Q2 2025, closing a stake of 63,731 shares — an estimated $569K sold.

Ameriprise first reported a position in TBPH in Q2 2014 and held it in 20 quarters. The position peaked at $36.4M in Q1 2020. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

  • Ameriprise reported no remaining Theravance Biopharma position as of Q2 2025 after selling out during the quarter.
  • Ameriprise sold 63,731 Theravance Biopharma shares in Q2 2025, an estimated $569K.
  • Ameriprise first reported a position in Theravance Biopharma in Q2 2014 and held it in 20 quarters.
  • Ameriprise's Theravance Biopharma position peaked at $36.4M in Q1 2020.
  • 135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on Ameriprise's 13F filing for Q2 2025, filed 14 Aug 2025.